Skip to main content

Advertisement

SpringerLink
Log in

Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Previous radiological investigations have generally shown the superiority of metabolic imaging in distinguishing high-grade from low-grade glioma, but the presence of an oligodendroglial component may affect the diagnostic accuracy. We investigated the diagnostic accuracy of PET imaging using 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) in distinguishing high-grade from low-grade glioma, in correlation with the oligodendroglial component.

Methods

The study population comprised adult patients who underwent preoperative PET imaging using both MET and FDG within 1 week and successful excision of the tumour tissue, which confirmed WHO grade II–IV glioma. We examined the tumour metabolic activity in terms of lesion-to-normal uptake ratios (L/N ratio) in both MET PET and FDG PET images. We assessed the correlation between the imaging results and the histological findings to determine the diagnostic accuracy of receiver operating characteristics (ROC) analysis in detecting high-grade tumours.

Results

We studied 46 patients with glioma (13 low-grade and 33 high-grade), including 26 with an oligodendroglial components. The L/N ratios of the PET images showed significantly higher metabolic activities in high-grade gliomas than in low-grade gliomas for both MET (4.29 ± 1.22 and 2.36 ± 0.72, respectively; p < 0.0001) and FDG (1.72 ± 0.91 and 0.77 ± 0.26, respectively; p = 0.0007) images, although significant overlaps in L/N ratio were observed between high-grade and low-grade gliomas. Excluding the 26 patents with an oligodendroglial component improved the separation for both MET (4.62 ± 1.14 vs. 2.16 ± 0.63; p < 0.001) and FDG (1.76 ± 0.87 vs. 0.71 ± 0.14; p < 0.05) images. The ROC analyses demonstrated the clinical utility of the metabolic radiotracers in distinguishing high-grade from low-grade gliomas, showing similar AUC values for MET (0.91) and FDG (0.92). Excluding the 26 patents with an oligodendroglial component also further improved the diagnostic accuracy for both MET (AUC 0.98), and FDG (AUC 1.00) images. The metabolic radiotracers were significantly correlated with the MIB-1 labelling index (R = 0.52, p < 0.05 for MET; R = 0.52, p < 0.05, for FDG) only in gliomas without an oligodendroglial component.

Conclusion

For better characterization of gliomas and for risk assessment, the results of metabolic PET imaging should be revised after obtaining the pathological report, because oligodendroglial differentiation may positively influence the substrate metabolism and thus complicated the preoperative evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104(2):238–53.

    Article  PubMed  Google Scholar 

  2. Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10(5):281–7.

    Article  CAS  PubMed  Google Scholar 

  3. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95(5):746–50.

    Article  PubMed  Google Scholar 

  4. Herholz K, Holzer T, Bauer B, Schröder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50(5):1316–22.

    Article  CAS  PubMed  Google Scholar 

  5. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol. 2008;29(10):1867–71.

    Article  CAS  PubMed  Google Scholar 

  6. Nojiri T, Nariai T, Aoyagi M, Senda M, Ishii K, Ishiwata K, et al. Contributions of biological tumor parameters to the incorporation rate of L-[methyl-11C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol. 2009;93(2):233–41.

    Article  CAS  PubMed  Google Scholar 

  7. Dähnert W. Radiology review manual (Dahnert, Radiology review manual). Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.

    Google Scholar 

  8. Yamaguchi S, Kobayashi H, Hirata K, Shiga T, Tanaka S, Murata J, et al. Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases. J Neurooncol. 2011;101(2):335–41.

    Article  PubMed  Google Scholar 

  9. Burger P, Scheithauer B. Diagnostic pathology: neuropathology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2012. p. 800.

    Google Scholar 

  10. Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70.

    Article  CAS  PubMed  Google Scholar 

  11. Delbeke D, Videlefsky S, Patton JA, Campbell MG, Martin WH, Ohana I, et al. Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med. 1995;36(11):2110–9.

    CAS  PubMed  Google Scholar 

  12. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29(2):176–82.

    Article  CAS  PubMed  Google Scholar 

  13. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, et al. Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103(3):498–507.

    Article  PubMed  Google Scholar 

  14. Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol. 2007;28(3):455–61.

    CAS  PubMed  Google Scholar 

  15. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25(9):1261–9.

    Article  CAS  PubMed  Google Scholar 

  16. Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210–4.

    Article  CAS  PubMed  Google Scholar 

  17. Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg. 2011;114(6):1640–7.

    Article  PubMed  Google Scholar 

  18. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27(7):1432–7.

    CAS  PubMed  Google Scholar 

  19. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, et al. [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol. 2010;96(2):231–9.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med. 2005;19(8):677–83.

    Article  PubMed  Google Scholar 

  21. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol. 1998;24(1):29–35.

    Article  CAS  PubMed  Google Scholar 

  22. Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, et al. 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol. 2013;34(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  23. Coons SW, Johnson PC. Regional heterogeneity in the DNA content of human gliomas. Cancer. 1993;72(10):3052–60.

    Article  CAS  PubMed  Google Scholar 

  24. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32(1):52–9.

    Article  CAS  PubMed  Google Scholar 

  25. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001;3(3):193–200.

    PubMed Central  CAS  PubMed  Google Scholar 

  26. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7(4):839–45.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Shigeo Oomagari, MSc, and Eriko Suzuki for their support.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Financial support

None.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, N15 W7, Kita-Ku, Sapporo, 0608638, Hokkaido, Japan

    Osamu Manabe, Naoya Hattori, Kenji Hirata, Kentaro Kobayashi, Tohru Shiga, Keiichi Magota & Nagara Tamaki

  2. Department of Neurosurgery, Hokkaido University Hospital, Sapporo, Japan

    Shigeru Yamaguchi, Shunsuke Terasaka, Hiroyuki Kobayashi & Hiroaki Motegi

  3. Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan

    Noriko Oyama-Manabe

  4. Department of Integrated Molecular Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Ken-ichi Nishijima & Yuji Kuge

  5. Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan

    Ken-ichi Nishijima & Yuji Kuge

Authors
  1. Osamu Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoya Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeru Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Hirata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kentaro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunsuke Terasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroaki Motegi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tohru Shiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keiichi Magota
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Noriko Oyama-Manabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ken-ichi Nishijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yuji Kuge
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nagara Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoya Hattori.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manabe, O., Hattori, N., Yamaguchi, S. et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging 42, 896–904 (2015). https://doi.org/10.1007/s00259-015-2996-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-015-2996-7

Keywords

Search

Navigation